tiaprofenic acid ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory agents, ibuprofen derivatives 2652 33005-95-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tiaprofenic acid
  • (RS)-Tiaprofenic acid
  • (+/-)-Tiaprofenic acid
  • tiaprofen
  • Molecular weight: 260.31
  • Formula: C14H12O3S
  • CLOGP: 2.54
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 54.37
  • ALOGS: -3.91
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.60 g O
0.60 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 38.42 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.08 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.62 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aspirin-exacerbated respiratory disease 53.02 50.46 9 645 886 63487482

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Musculoskeletal discomfort 123.01 57.51 32 1005 19803 79723548
Limb discomfort 102.70 57.51 31 1006 32819 79710532
Localised infection 98.60 57.51 31 1006 37544 79705807
Gait inability 84.92 57.51 31 1006 58886 79684465
Liver disorder 78.70 57.51 31 1006 72386 79670965

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AE11 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Propionic acid derivatives
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:88188 allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Rheumatoid arthritis indication 69896004 DOID:7148
Osteoarthritis indication 396275006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.82 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 7.10 WOMBAT-PK SCIENTIFIC LITERATURE
Prostaglandin G/H synthase 1 Enzyme INHIBITOR IC50 5.90 WOMBAT-PK SCIENTIFIC LITERATURE

External reference:

IDSource
D01325 KEGG_DRUG
C0076653 UMLSCUI
CHEBI:32221 CHEBI
CHEMBL365795 ChEMBL_ID
DB01600 DRUGBANK_ID
C021270 MESH_SUPPLEMENTAL_RECORD_UI
5468 PUBCHEM_CID
3320 INN_ID
1LS1T6R34C UNII
38253 RXNORM
003468 NDDF
329889002 SNOMEDCT_US
395902007 SNOMEDCT_US

Pharmaceutical products:

None